{
    "doi": "https://doi.org/10.1182/blood.V106.11.109.109",
    "article_title": "Targeting Bcl-2 as Therapy for Multiple Myeloma. ",
    "article_date": "November 16, 2005",
    "session_type": "Oral Sessions",
    "abstract_text": "Mitochondrial signaling is an important component of chemotherapy-induced apoptosis in cancer cells ( Korsmeyer, SJ, 2004  Cell , 111 : 205 \u2013219 ). Members of the Bcl-2 family of proteins regulate, in part, the release of apoptogenic factors, such as cytochrome-c from the intermembrane space into the cytosol, thereby initiating caspase-9-mediated cell-death signaling cascade (Reed, SJ 1997, 34: 9\u201319; Kirkin et al, 2004 , Biochim Biophys Acta. 2204 , 1644 : 229 \u2013249 ). Overexpression of Bcl-2 or Bcl-x(L) confers resistance to chemotherapy in cancer cells, including MM ( Letai, A 2004  Cancer cell , 6 : 241 \u2013249 ; Chauhan et al, 2005 , Annu Rev Pharmocol Toxicol , 45 : 465 \u2013476 ). Here we utilized ABT-737 (Abbott Laboratories), a potent small-molecule inhibitor of anti-apoptotic proteins Bcl-2, Bcl-x(L) and Bcl-w with markedly higher affinity than previously reported compounds ( Oltersdorf, Elmore, &Shoemaker et al, Nature  2005 , 435 ; 677 \u201381 ). We show that ABT-737 inhibits the growth of MM cells, including those resistant to conventional agents dexamethasone, melphalan or doxorubicin. Examination of purified patient MM cells demonstrated similar results. Importantly, ABT-737 also decreases the viability of CD138 + tumor cells obtained from Bortezomib-refractory MM patient. In contrast, no significant toxicity of ABT-737 was observed against peripheral blood mononuclear cells from normal healthy donors or CD138 \u2212 MM patient cells. Moreover, ABT-737 does not affect the viability of MM patient-derived bone marrow stromal cells (BMSCs). Mechanistic studies show that ABT-737-triggered apoptosis in MM cells is associated with activation of caspase-8, caspase-9, and caspase-3, followed by proteolytic cleavage of poly (ADP) ribose (PARP) enzyme. Finally, ABT-737 enhances the anti-MM activity of Bortezomib or Melphalan, without significant toxicity in normal cells. Collectively, these findings provide the rationale for clinical evaluation of ABT-737 alone, or in combination with Bortezomib or Melphalan, to enhance MM cell killing, overcome drug-resistance, and improve patient outcome in MM.",
    "topics": [
        "abt-737",
        "bcl2 gene",
        "bortezomib",
        "caspase-3",
        "caspase-8",
        "caspase-9",
        "caspases",
        "chemotherapy regimen",
        "cytochrome c",
        "dexamethasone"
    ],
    "author_names": [
        "Dharminder Chauhan, PhD",
        "Mugdha Velankar, M.S",
        "Teru Hideshima, Ph.D",
        "Constantine Mitsiades, Ph.D",
        "Laurence Catley, M.D",
        "Noopur Raje, M.D",
        "Robert Schlossman, M.D",
        "Paul Richardson, M.D",
        "Kenneth C. Anderson, M.D."
    ],
    "author_dict_list": [
        {
            "author_name": "Dharminder Chauhan, PhD",
            "author_affiliations": [
                "Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Mugdha Velankar, M.S",
            "author_affiliations": [
                "Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Teru Hideshima, Ph.D",
            "author_affiliations": [
                "Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Constantine Mitsiades, Ph.D",
            "author_affiliations": [
                "Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Laurence Catley, M.D",
            "author_affiliations": [
                "Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Noopur Raje, M.D",
            "author_affiliations": [
                "Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Robert Schlossman, M.D",
            "author_affiliations": [
                "Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Paul Richardson, M.D",
            "author_affiliations": [
                "Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Kenneth C. Anderson, M.D.",
            "author_affiliations": [
                "Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-04-27T09:30:35",
    "is_scraped": "1"
}